Lipid Or Oil Patents (Class 424/283.1)
-
Patent number: 7648706Abstract: The present invention provides a safe and effective vaccine composition against West Nile virus disease. An immunogenically active component of West Nile virus or plasmid DNA, an adjuvant such as a metabolizable oil, and a pharmacologically acceptable carrier are formulated into an immunizing vaccine. The invention also provides a method for the prevention or amelioration of West Nile disease, such as encephalitis, in equidae by administering the vaccine composition herein set forth.Type: GrantFiled: October 30, 2006Date of Patent: January 19, 2010Assignee: Wyeth LLCInventor: Hsien-Jue Chu
-
Patent number: 7648705Abstract: The present invention provides a safe and effective vaccine composition against West Nile virus disease. An immunogenically active component of West Nile virus or plasmid DNA, an adjuvant such as a metabolizable oil, and a pharmacologically acceptable carrier are formulated into an immunizing vaccine. The invention also provides a method for the prevention or amelioration of West Nile disease, such as encephalitis, in equidae by administering the vaccine composition herein set forth.Type: GrantFiled: October 30, 2006Date of Patent: January 19, 2010Assignee: Wyeth LLCInventor: Hsien-Jue Chu
-
Patent number: 7641911Abstract: The present invention is directed to novel adjuvant compositions, which target the cellular and/or humoral arms of immunity. According to an embodiment of the invention, an oil-in-water adjuvant composition is provided that comprises: (a) water; (b) a metabolizable oil comprising at least one branched or unbranched long-chain hydrocarbon moiety; (c) a steroid; and (d) a saponin.Type: GrantFiled: January 25, 2005Date of Patent: January 5, 2010Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Gary S. Ott, Manmohan Singh, Derek O'Hagan
-
Patent number: 7638314Abstract: A process for producing biodiesel has been invented by first extracting lipids from the sludges generated during primary and/or biological treatment of municipal, agricultural, and industrial wastewaters using primary, secondary, and tertiary treatments followed by the transesterification of the extracted lipids using transesterification conversion into alcohol-based esters. The resulting products from this process include biodiesel, glycerol, lipid-free proteins, various other useful chemicals and an aqueous-based substrate well suited for optimized digestion within subsequent biological digestion (either aerobic or anaerobic). The lipids extracted from the sludges containing high levels of microorganisms are phospholipids which can also be directly used as lecithin.Type: GrantFiled: October 4, 2004Date of Patent: December 29, 2009Assignee: Mississippi State UniversityInventors: Mark E. Zappi, William Todd French, Rafael Hernandez, Stephen Thomas Dufreche, Darrell L. Sparks, Jr.
-
Publication number: 20090291103Abstract: Measurements of the squalene content in oil-in-water emulsions can be used as a way of checking for problems during production. In particular, it has been found that a drop in squalene content can indicate that filtration problems occurred. Testing the squalene content in the final lots is easier than investigating the characteristics of the filter, and so a squalene assay simplifies the quality control of oil-in-water emulsions.Type: ApplicationFiled: November 6, 2007Publication date: November 26, 2009Applicant: NOVARTIS AGInventor: Norbert Klein
-
Patent number: 7608279Abstract: The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified or weakly purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group comprising an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof.Type: GrantFiled: February 7, 2008Date of Patent: October 27, 2009Assignee: Merial LimitedInventors: Alexis Guy Andre Parisot, Stephanie Marie-Catherine Desgouilles-Blechet, Catherine Charreyre
-
Patent number: 7608246Abstract: The present invention is directed to pharmaceutical compositions that contain a combination of apolipoprotein E and an antigenic lipid. The compositions may be administered to a subject for the purpose of inducing an immune response against the lipid and in immunization protocols.Type: GrantFiled: September 5, 2006Date of Patent: October 27, 2009Assignee: The Brigham and Women's Hospital, Inc.Inventors: Peter van den Elzen, Michael B. Brenner
-
Publication number: 20090214592Abstract: An immunogenic composition comprising: (i) an antigen; (ii) an aluminum phosphate adjuvant; and (iii) a 3-O-deacylated monophosphoryl lipid A adjuvant. Components (ii) and (iii) can also be used as a separate adjuvant system. Various features of the compositions are disclosed, including that at least 50% of the 3-O-deacylated monophosphoryl lipid A adjuvant should be adsorbed to the aluminum phosphate adjuvant. The adjuvant mixture is particularly useful with hepatitis B virus surface antigen.Type: ApplicationFiled: February 16, 2006Publication date: August 27, 2009Inventor: Derek O'Hagan
-
Publication number: 20090191227Abstract: The disclosure provides adjuvants, immunogenic compositions, and methods useful for vaccination and immune response. In particular, the disclosure provides a class of adjuvants comprising cationic lipid:co-lipid mixtures and methods for delivering formulated compositions.Type: ApplicationFiled: May 23, 2008Publication date: July 30, 2009Applicant: Vical IncorporatedInventors: Jukka Hartikka, Sean M. Sullivan, Joel D. Enas, Alain Rolland
-
Patent number: 7563446Abstract: Disclosed are methods and compositions for the prevention and treatment of cancers using lipid-carrier protein conjugate compositions for generating lipid-specific immune responses in an animal. Also disclosed are methods for making phosphatidylserine conjugate compositions and their formulation for use in a variety of pharmaceutical applications including the detection and treatment of a variety of cancers and related conditions.Type: GrantFiled: August 31, 2004Date of Patent: July 21, 2009Assignee: Board of Regents, The University of Texas SystemInventor: Alan J. Schroit
-
Publication number: 20090169636Abstract: Immunogenic compositions are described herein which comprise microparticles that further comprise a biodegradable polymer. The microparticle compositions also comprise a cationic polysaccharide and an immunological species selected from an antigen, an immunological adjuvant and a combination thereof. Also described are methods of making such compositions and methods of administering such compositions. Methods of modulating the release rate of immunological species from microparticles are also described. These methods comprise varying the ratio of the cationic polysaccharide relative to the biodegradable polymer within the microparticles.Type: ApplicationFiled: February 24, 2007Publication date: July 2, 2009Inventors: Derek O' Hagan, Manmohan Singh, Janet Wendorf, Jina Kazzaz, Padma Malyala
-
Patent number: 7534443Abstract: An oil-in-water emulsion that comprise a bacterial component as an active ingredient as well as essentially an oil, surfactant, and a stabilizer, and that can be used as an agent for immunotherapy, and the preparation therefor are provided.Type: GrantFiled: July 16, 1999Date of Patent: May 19, 2009Assignees: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Ichiro Azuma, Norio Hamamatsu, Toshio Fujinaga
-
Patent number: 7517953Abstract: An improved pasteurization protocol for pasteurizing microbial cells is disclosed. The protocol has three stages, a first heating stage, a second plateau stage at which the cells are held at a (maximum and) constant temperature, and a third cooling stage. Both the heating and the cooling stages are rapid, with the temperature of the cells passing through 40 to 80° C. in no more than 30 minutes in the heating stage. The heating rate is at least 0.5° C./minute and during cooling is at least ?0.5° C./minute. The plateau maximum temperature is from 70 to 85° C. By plotting the pasteurization protocol on a time (t, minutes) versus temperature (T, ° C.) graph, one obtains a trapezium having an area less than 13,000° C. minute. Not only does this result in a smaller energy input (and so a reduction in costs), but a better quality (and less oxidized) oil results having a peroxide value (POV) of less than 1.5 and an anisidine value (AnV) of less than 1.0.Type: GrantFiled: June 20, 2003Date of Patent: April 14, 2009Assignee: DSM IP Assets B.V.Inventors: Albert Schaap, Daniel Verkoeijen
-
Publication number: 20090047306Abstract: An adjuvant composition comprises a Th1-activating alkaloid, optionally further comprising an auxiliary adjuvant selected from a type 2 adjuvant (e.g. alum and/or MF59), a type 1 adjuvant and/or a balanced adjuvant. Vaccines comprising the adjuvant composition include nucleic acid(s) which encode one or more antigenic protein(s); protein(s) or peptide(s); glycoprotein(s); polysaccharide(s) (e.g. carbohydrate(s)); fusion protein(s); lipid(s); glycolipid(s); peptide mimic(s) of polysaccharides carbohydrate(s) and a protein(s) in admixture; carbohydrate-protein conjugate(s); cells or extracts thereof; dead or attenuated cells or extracts thereof; tumour cells or extracts thereof; viral particles (e.g. attenuated viral particles or viral components); allergen(s) mixtures thereof.Type: ApplicationFiled: January 21, 2005Publication date: February 19, 2009Applicant: M N L PHARMA LIMITEDInventors: Robert James Nash, Alison Ann Watson, Emma Louisa Evinson
-
Patent number: 7425336Abstract: The present invention encompasses influenza vaccines, in particular canine influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing influenza antigens, epitopes or immunogens which can be used to protect animals, in particular dogs, against influenza.Type: GrantFiled: November 1, 2005Date of Patent: September 16, 2008Assignee: Mevial LimitedInventors: Jules Maarten Minke, Kemal Karaca, Jiansheng Yao
-
Publication number: 20080187553Abstract: A pharmaceutical formulation for parenteral or mucosal administration of antigens and/or vaccines to humans and animals, comprising monglyceride preparations having at least 80% monoglyceride content and where the acyl group contains from 6 to 24 carbon atoms, together with fatty acids where the number of carbon atoms may be varied between 4 and 22.Type: ApplicationFiled: March 26, 2008Publication date: August 7, 2008Applicant: Eurocine ABInventor: Ulf Schroder
-
Publication number: 20080145387Abstract: The invention provides adjuvants, immunogenic compositions, and methods useful for polynucleotide-based vaccination and immune response. In particular, the invention provides an adjuvant of cytofectin:co-lipid mixture wherein cytofectin is GAP-DMORIE.Type: ApplicationFiled: August 17, 2007Publication date: June 19, 2008Applicant: Vical IncorporatedInventor: Carl J. Wheeler
-
Patent number: 7381422Abstract: The present invention relates to a novel method for producing formulations comprising a polynucleotide, block copolymer and cationic surfactant. The formulations produced by the current method are suitable for use in polynucleotide based medicaments. A suitable method of production disclosed herein additionally comprises cold filtering a mixture of a polynucleotide, block copolymer and cationic surfactant, thereby sterilizing the formulation. The method of the present invention also eliminates the need for thermal cycling of the formulation, thereby reducing the time and expense required to produce large quantities of a formulation during commercial manufacturing. The present invention also relates to novel cationic lipids.Type: GrantFiled: December 2, 2003Date of Patent: June 3, 2008Assignee: Vical IncorporatedInventors: Joel Enas, Andrew Geall
-
Publication number: 20080124350Abstract: A vaccine delivery system comprising adjuvant and nanoparticles comprising an immunogenic agent is provided. A method of immunizing an animal comprising administering a nanoparticle-based vaccine delivery system is also provided.Type: ApplicationFiled: January 25, 2008Publication date: May 29, 2008Applicant: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATIONInventors: Russell Mumper, Zhengrong Cui
-
Patent number: 7374751Abstract: Adjuvant compositions comprising an effective amount IL-12 and QS-21 are disclosed. Immunogenic, vaccine and pharmaceutical compositions comprising a mixture of antigen and an adjuvant composition comprising an effective amount of IL-12 and QS-21 are also disclosed. These compositions elicit functional cell-mediated and humoral immune responses against at least one antigen. Methods of using the disclosed compositions are also disclosed.Type: GrantFiled: June 21, 2001Date of Patent: May 20, 2008Assignee: Wyeth Holdings CorporationInventor: Gerald E. Hancock
-
Patent number: 7371395Abstract: The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified or weakly purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group comprising an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof.Type: GrantFiled: July 26, 2004Date of Patent: May 13, 2008Assignee: Merial LimitedInventors: Alexis Guy Andre Parisot, Stephanie Marie-Catherine Desgouilles-Blechet, Catherine Charreyre
-
Patent number: 7357936Abstract: The present invention provides vaccine and adjuvant formulation comprising an immunostimulant and a metal salt. The immunostimulant is adsorbed onto a particle of metal salt and the resulting particle is essentially devoid of antigen.Type: GrantFiled: October 8, 1999Date of Patent: April 15, 2008Assignee: SmithKline Beecham Biologicals, SAInventor: Nathalie Garcon
-
Patent number: 7329410Abstract: A method for enhancing or inducing an immune response to WT1 is disclosed. In particular, the method comprises administering to a patient an immunogenic composition comprising an isolated polypeptide consisting of amino acids 1-249 of WT1 and a non-specific immune response enhancer.Type: GrantFiled: October 9, 2000Date of Patent: February 12, 2008Assignees: Corixa Corporation, University of WashingtonInventors: Alexander Gaiger, Martin A. Cheever
-
Patent number: 7309493Abstract: Inactivated scours vaccines for immunization and protection of bovine animals from disease caused by infection with bovine rotavirus and bovine coronavirus, which comprise and effective amount of at least one inactivated viral strain are described. Polyvalent inactivated vaccines further comprising an effective amount of an antigenic component which is protective against one or more additional pathogenic organisms or viruses are also disclosed. Said vaccines are prepared from one or more strains of rota- and coronavirus, C. perfringens Type C bacteria and E. coli bacteria, and combinations thereof. Preferably, a polyvalent inactivated vaccine is provided for parenteral administration. Passive immunity is achieved in neonatal calves via immunization of pregnant cows prior to birth.Type: GrantFiled: August 1, 2005Date of Patent: December 18, 2007Assignee: Novartis AGInventors: Kelly Knape, Stephanie Dykstra, Mary Tinant
-
Patent number: 7276579Abstract: An immunogenic proteoliposome containing a transmembrane protein or oligomeric complexes containing such proteins, including viral envelope glycoproteins, in a lipid membrane around an elliptoid or spherical shape. The shape preferably also contains an attractant such as streptavidin or avidin and the lipid membrane contains a moiety that binds to the attractant such as biotin. The immunogenic transmembrane protein is bound to a ligand which is anchored in the shape. Methods for making the immunogenic proteoliposomes are provided uses of the proteoliposome are described, including their use as immunogens to elicit immune reaction, and their use in screening assays, including their use as antigens to screen antibody libraries, as well as for drug screening and the identification of ligands.Type: GrantFiled: December 27, 2001Date of Patent: October 2, 2007Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Richard T. Wyatt, Joseph G. Sodroski, Tajib Mirzabekov, Christoph Grunder
-
Patent number: 7259012Abstract: The invention concerns a method for differentiating precursor cells into mature dendritic cells, comprising placing the precursor cells in a medium suitable for their differentiation and adding to the medium, in a predetermined amount, at least one fraction of oxidized lipoproteins selected among oxidized very low density lipoproteins (VLDLs) and/or oxidized intermediate density lipoproteins (IDLs) and/or oxidized low density lipoproteins (LDLs). The precursor cells are preferably monocytes.Type: GrantFiled: July 8, 2002Date of Patent: August 21, 2007Assignees: Biomerieux, Institut National de la Sante et de la Recherche MedicaleInventors: Vincent Lotteau, Patrice Andre
-
Patent number: 7255867Abstract: Effective stimulation of immune responses is achieved through the use of a group A streptococcal antigen combined with proteosome adjuvant. The compositions are provided in particular for intranasal administration. The vaccine compositions are provided for use in inducing an immune response in an individual for the treatment or prophylaxis of group A streptococcal infection in an individual, preferably via prevention or reduction of colonisation of the throat following intranasal administration.Type: GrantFiled: November 13, 2003Date of Patent: August 14, 2007Assignees: ID Biomedical Corporation of Quebec, The Council of the Queensland Institute of Medical ResearchInventors: George H Lowell, George L White, Michael R Batzloff, David S Burt, Tomas B Leanderson, Michael F Good
-
Patent number: 7223739Abstract: Reagents useful in nucleic acid immunization techniques are described. More particularly, adjuvanted genetic vaccine compositions are described, as are methods of using those compositions for inducing an enhanced immune response against a selected antigen.Type: GrantFiled: November 3, 1999Date of Patent: May 29, 2007Assignee: Powderject Vaccines, Inc.Inventors: Joel R. Haynes, Georg Widera, James T. Fuller, Timothy Shipley, Deborah Fuller, Mary Wu
-
Patent number: 7189418Abstract: The present invention provides a method for extracting a lipid mixture having a high percentage of phospholipids comprising polyunsaturated fatty acids. The method comprises the steps of (a) heating the viscera of fish with hot water or steam; and (b) extracting from the heated viscera of fish, using a solvent, the lipid mixture containing phospholipids comprising polyunsaturated fatty acids. The lipid mixture obtained by the present method contains phosphatidylserine comprising docosahexaenoic acid and phosphatidylethanolamine comprising docosahexaenoic acid in high concentration.Type: GrantFiled: February 12, 2003Date of Patent: March 13, 2007Assignees: Kabushikikaisha Maruhachi Muramatsu, Shizuoka Prefectural GovernmentInventors: Seiichi Hiratsuka, Toshihiro Suzuki, Masayuki Hashidume, Youko Matsue, Tomoko Kitagawa, Masaaki Yokoyama, Masami Tamura, Tatsuya Fujii, Noriyuki Muramatsu
-
Patent number: 7147862Abstract: The present invention provides vaccine compositions comprising 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccines compositions are potent inducers of CTL and ? IFN responses.Type: GrantFiled: August 12, 1997Date of Patent: December 12, 2006Assignee: SmithKline Beecham Biologicals (S.A.)Inventors: Jean-Paul Prieels, Nathalie Marie-Josephe Claude Garcon-Johnson, Moncef Slaoui, Pietro Pala
-
Patent number: 7122191Abstract: This invention provides submicron oil-in-water emulsions useful as a vaccine adjuvant for enhancing the immunogenicity of antigens. The present invention also provides vaccine compositions containing an antigen combined with such emulsions intrinsically or extrinsically. Methods of preparing the emulsions and vaccines are also provided by the present invention.Type: GrantFiled: April 1, 2005Date of Patent: October 17, 2006Assignee: Pfizer Inc.Inventors: Paul Joseph Dominowski, Pamela K. Klose, Richard L. Krebs, Ramasamy M. Mannan
-
Patent number: 7078388Abstract: DNA vaccine against a pathogen affecting farm animals, in particular bovines or porcines, comprising a plasmid containing a nucleotide sequence encoding an immunogen of a pathogen of the animal species considered, under conditions allowing the in vivo expression of this sequence, and a cationic lipid containing a quaternary ammonium salt, of formula in which R1 is a saturated or unsaturated linear aliphatic radical having 12 to 18 carbon atoms, R2 is another aliphatic radical containing 2 or 3 carbon atoms, and X a hydroxyl or amine group, this lipid being preferably DMRIE.Type: GrantFiled: January 16, 2001Date of Patent: July 18, 2006Assignee: MerialInventors: Jean-Christophe Francis Audonnet, Laurent Bernard Fischer, Simona Barzu-Le-Roux
-
Patent number: 7063855Abstract: A composition is for feeding aquacultural prey organisms such as Artemia and rotifiers, comprising a lipid component comprising at least 25 wt % of phospholipids and providing a DHA content of at least 30 wt %. The lipid component is preferably derived from marine organisms such as fishmeal, phytoplankton or zoo plankton biomass. The composition is used for providing prey organisms having a high content of highly-unsaturated fatty acids (HUFAs) suitable for aquaculture of fish including halibut, turbot, bass and crustaceans and molluses.Type: GrantFiled: January 15, 2001Date of Patent: June 20, 2006Inventors: Baldur Hjaltason, Gudmundur G. Haraldsson, Olafur Halldorsson
-
Patent number: 7052704Abstract: Fatty acid derivatives of sulfhydryl-containing compounds (for example, sulfhydryl-containing peptides or proteins) comprising fatty acid-conjugated products with a disulfide linkage are employed for delivery of the compounds to mammalian cells. This modification markedly increases the absorption of the compounds by mammalian cells relative to the rate of absorption of the unconjugated compounds, as well as prolonging blood and tissue retention of the compounds. Moreover, the disulfide linkage in the conjugate is quite labile in the cells and thus facilitates intracellular release of the intact compounds from the fatty acid moieties.Type: GrantFiled: May 1, 2001Date of Patent: May 30, 2006Assignee: University of Southern CaliforniaInventors: Wei-Chiang Shen, Hossein M. Ekrami
-
Patent number: 7033612Abstract: There is provided a composition for the prevention and treatment of age-related physical and mental disorders that includes phospholipids that have been extracted from chick embryos aged between about 6 days old and about 14 days old. Also provided is a method for extracting these phospholipids by incubating them for between about 6 days to about 14 days. The chick embryos are then prepared for chemical extraction, and the lipids are extracted from the chick embryos. Further provided is a method for preventing and treating age-related physical and mental disorders, in human subjects in need thereof, by administering a sufficient dosage of a composition including phospholipids extracted from chick embryos incubated for between about 6 days and about 14 days to a human subject.Type: GrantFiled: January 3, 2003Date of Patent: April 25, 2006Inventors: David S. Kang, Chunghee Kimberly Kang
-
Patent number: 6974577Abstract: Inactivated scours vaccines for immunization and protection of bovine animals from disease caused by infection with bovine rotavirus and bovine coronavirus, which comprise and effective amount of at least one inactivated viral strain are described. Polyvalent inactivated vaccines further comprising an effective amount of an antigenic component which is protective against one or more additional pathogenic organisms or viruses are also disclosed. Said vaccines are prepared from one or more strains of rota- and coronavirus, C. perfringens Type C bacteria and E. coli bacteria, and combinations thereof. Preferably, a polyvalent inactivated vaccine is provided for parenteral administration. Passive immunity is achieved in neonatal calves via immunization of pregnant cows prior to birth.Type: GrantFiled: February 4, 2001Date of Patent: December 13, 2005Assignee: Novartris AGInventors: Kelly Knape, Stephanie Dykstra, Mary Tinant
-
Patent number: 6951658Abstract: The invention is a method and supplement for treatment of symptoms of Alzheimer's disease, dementia, depression, and combination thereof, comprising: from about 20 wt % to about 70 wt % emu oil, wherein the emu oil further comprises from about 1 wt % to about 12 wt % linolenic acid; from about 5 wt % to about 30 wt % l-arginine; from about 5 wt % to about 30 wt % pyroglutamate; from about 0.5. wt % to about 20 wt % B-12 methylcobalamin; and from about 0.5 wt % to about 20 wt % calcium, wherein the supplement is adapted for crossing a blood brain barrier, and for fortification of phospholipids in neurotransmitters of a brain to increase cell proliferation for treatment of symptoms of Alzheimer's disease, dementia, depression, and combinations thereof.Type: GrantFiled: July 8, 2003Date of Patent: October 4, 2005Assignee: Pearson Research & Development LimitedInventors: Maurine Pearson, Teresa Leigh Barr
-
Patent number: 6936260Abstract: A tuberculosis (TB) vaccine composition is disclosed. The composition comprises, as adjuvant, one or more substances selected from a) monoglyceride preparations having at least 80% monoglyceride content and b) fatty acids of the general formula CH3—(CH2)n—COOH where “n” may be varied between 4 and 22, and where the acyl chain may contain one or more unsaturated bonds, and as immunizing component, inactivated, e.g. heat killed or formalin killed, Mycobacterium tuberculosis bacteria.Type: GrantFiled: February 9, 2000Date of Patent: August 30, 2005Assignee: Eurocine ABInventors: Ulf Schroder, Stefan Svenson
-
Patent number: 6932972Abstract: Novel combined vaccine composition preferentially for administration to adolescents are provided, comprising a hepatitis B viral antigen and a herpes simplex viral antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen or inactivated attenuated virus, an HPV antigen, a V2V antigen, a HCMV antigen, a Toxoplasma gondii antigen. The vaccine compositions are formulated with an adjuvant which is a preferential stimulator of TH1 cell response such as 3D-MPL and QS21.Type: GrantFiled: August 23, 2002Date of Patent: August 23, 2005Assignee: SmithKline Beecham Biologicals S.A.Inventors: Jean Stephenne, Martine Anne Cecile Wettendorff
-
Patent number: 6919084Abstract: An immunogenic preparation or vaccine against avian pneumovirosis, comprising an antigen of the avian pneumovirus strain C990427, in a vehicle or excipient which is acceptable from the veterinary point of view and, optionally, an adjuvant.Type: GrantFiled: May 24, 2002Date of Patent: July 19, 2005Assignee: MerialInventor: Sylvain Gabriel Goutebroze
-
Patent number: 6893644Abstract: A vaccine formulation for the treatment or prophylaxis of hepatitis, especially hepatitis, especially hepatitis B, infections is provided comprising the hepatitis antigen and a suitable carrier such as alum in combination with 3-O-deacylated monophosphoryl lipid. A combination vaccines including the vaccine formulation are also described.Type: GrantFiled: June 19, 2003Date of Patent: May 17, 2005Assignee: SmithKline Beecham Biologicals s.a.Inventors: Nathalie Marie-Josephe Claude Garcon-Johnson, Pierre Hauser, Clothilde Thiriart, Pierre Voet
-
Patent number: 6890540Abstract: A vaccine formulation against a microorganism is disclosed. The formulation comprises: as adjuvant, one or more substances selected from a) monoglyceride preparations having at least 80% monoglyceride content and b) fatty acids of the general formula CH3—(CH2)n—COOH where “n” may be varied between 4 and 22, and where the acyl chain may contain one or more unsaturated bonds, and as immunizing component, an immunogenic product consisting of antigenically active carbohydrate moieties (ACM) derived from said microorganism which are each covalently coupled, possibly via identical divalent bridge groups, to immunologically active carriers (IAC). The vaccine formulation is e.g. against Mycobacterium tuberculosis and in that case the formulation may comprise, as adjuvant, a mixture of mono-olein and oleic acid, and possibly soybean oil, and, as immunizing component, lipoarabinomamman-tetanus toxoid (LAM-TT).Type: GrantFiled: February 9, 2000Date of Patent: May 10, 2005Assignee: Eurocine ABInventors: Ulf Schroder, Stefan Svenson
-
Patent number: 6852705Abstract: Improved vaccines or immunogenic or immunological compositions, and methods for making and using the same.Type: GrantFiled: January 19, 2001Date of Patent: February 8, 2005Assignee: MerialInventors: Jean-Christophe Francis Audonnet, Laurent Bernard Fischer, Simona Barzu-Le-Roux
-
Patent number: 6844001Abstract: The present invention comprises novel polyoxyethylene/polyoxypropylene block copolymer compositions and compounds. The compositions comprise block copolymers that are high molecular weight molecules, and are useful in gene therapy methods.Type: GrantFiled: April 2, 2002Date of Patent: January 18, 2005Assignee: Cyt Rx CorporationInventors: Mannarsamy Balasubramanian, Mark Joseph Newman, R. Martin Emanuel, Carlos A. Rivera-Marrero, Charles William Todd, Robert Newton Brey, III
-
Patent number: 6814971Abstract: The invention relates to adjuvants that contain a lecithin, an oil and an amphiphilic surfactant and that are capable of forming a stable oil-in-water emulsion vaccine so as to minimize local reactions to the vaccine in the injected animal.Type: GrantFiled: March 13, 2003Date of Patent: November 9, 2004Assignee: Pfizer Inc.Inventors: David S. Roberts, Leroy A. Swearingin, Don A. Dearwester
-
Patent number: 6806354Abstract: Disclosed are methods and compositions for the prevention and treatment of cancers using lipid-carrier protein conjugate compositions for generating lipid-specific immune responses in an animal. Also disclosed are methods for making phosphatidylserine conjugate compositions and their formulation for use in a variety of pharmaceutical applications including the detection and treatment of a variety of cancers and related conditions.Type: GrantFiled: October 9, 2001Date of Patent: October 19, 2004Assignee: Board of Regents University of Texas SystemInventor: Alan J. Schroit
-
Patent number: 6797276Abstract: A transcutaneous immunization system where the topical application of an adjuvant and an antigen or nucleic acid encoding for an antigen, to intact skin induces a ystemic or mucosol antibody response. The immune response so elicited can be enhanced by physical or chemical skin penetration enhancement.Type: GrantFiled: February 25, 1999Date of Patent: September 28, 2004Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Gregory M. Glenn, Carl R. Alving
-
Patent number: 6793923Abstract: The present invention is concerned with vaccines and their preparation. An effective long-term immune response, especially in mammals, can be produced using a vaccine comprising an antigen encapsulated in liposomes, a suitable adjuvant and a carrier comprising a continuous phase of a hydrophobic substance. The vaccine is particularly effective in eliciting the production of antibodies that recognize epitopes of native proteins.Type: GrantFiled: November 6, 2001Date of Patent: September 21, 2004Assignee: Immunovaccine Technologies, Inc.Inventors: Robert George Brown, William Pohajdak, Warwick Charles Kimmins
-
Patent number: 6787154Abstract: The present invention is directed to artificial antigen presenting cells and methods of making artificial antigen presenting cells. Such artificial antigen presenting cells may be used in certain methods of isolating and expanding T cell populations as well as modulating T cell responses. Additionally, the present invention provides novel methods for the identification and isolation of antigen-specific T cells. The methods provide for the construction of liposomes containing MHC:peptide complexes, accessory molecules, co-stimulatory molecules, adhesion molecules, and other molecules irrelevant to T cell binding or modulation that are used in the binding of artificial antigen presenting cells to solid support systems that may be used in the retrieval and identification of antigen-specific T cells.Type: GrantFiled: January 9, 2001Date of Patent: September 7, 2004Inventor: Salvatore Albani
-
Patent number: 6780421Abstract: An amphipathic compound including a sterol-derived lipophilic grouping bound to a cationic grouping for use as an adjuvant in the delivery of a vaccine composition. In a particular embodiment, the lipophilic grouping is a cholesterol derivative and the cationic grouping is a quaternary ammonium or a protonatable amine. A vaccine composition including one or more antigens with at least one amphipathic compound having a sterol-derived lipophilic grouping bound to a cationic grouping, is also disclosed.Type: GrantFiled: September 9, 1997Date of Patent: August 24, 2004Assignee: Aventis Pasteur SAInventors: Jean Haensler, Emmanuelle Trannoy, Jorge Ronco